Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardinal Health, Inc. (NYSE: CAH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Cardinal Health is an Ohio corporation whose common shares trade on the New York Stock Exchange under the symbol CAH, as noted in multiple Form 8-K filings. These documents give investors detailed insight into the company’s financial condition, governance, capital structure, and material events.
Cardinal Health regularly files Form 8-K current reports to announce significant developments. Recent 8-K filings include disclosures about quarterly and annual financial results, updates to fiscal 2026 non-GAAP earnings per share outlook, entry into material definitive agreements such as credit facilities and receivables purchase amendments, public offerings of notes to help fund acquisitions like Solaris Health, and the completion of those offerings. Other 8-Ks document matters such as the 2025 Annual Meeting of Shareholders and voting results on director elections, say-on-pay, and auditor ratification.
The company’s definitive proxy statement on Schedule 14A (DEF 14A) offers extensive information on corporate governance, Board composition, executive compensation, and shareholder voting items. Cardinal Health’s proxy materials describe its strategic priorities, fiscal performance highlights, Board skills and refreshment, and engagement with shareholders.
Through Stock Titan, users can review Cardinal Health’s periodic and current reports and use AI-powered tools to summarize key points from lengthy filings. These tools help explain complex sections, highlight items such as non-GAAP metrics definitions, capital markets transactions, and credit agreements, and make it easier to track themes like Specialty growth, distribution network investments, and capital allocation. The filings page also surfaces relevant exhibits, including indentures, underwriting agreements, and amendments to financing arrangements, giving a structured view of Cardinal Health’s obligations and governance framework.
Cardinal Health reported strong growth for the quarter ended March 31, 2026. Revenue rose 11% to $60.9 billion, driven mainly by higher branded and specialty pharmaceutical sales, including increased GLP‑1 demand. Pharma segment revenue reached $56.1 billion, while Other grew 31% on at‑Home Solutions, Nuclear and Precision Health, and OptiFreight®.
GAAP operating earnings fell 30% to $509 million due to a $184 million goodwill impairment at the Navista & ION oncology MSO unit and the absence of prior‑year litigation recoveries. However, non‑GAAP operating earnings rose 18% to $956 million, and non‑GAAP diluted EPS increased 35% to $3.17, reflecting acquisitions of MSO platforms and Advanced Diabetes Supply Group and a strong generics program.
The company completed the $1.9 billion Solaris Health acquisition, helping lift goodwill to $11.4 billion, and ended the period with $3.9 billion of cash and equivalents. Liquidity is supported by unused credit facilities and a receivables program, while Cardinal continues making opioid settlement payments and investing in share repurchases and dividends. Tariffs remain a headwind, particularly in Global Medical Products and Distribution, where segment profit for the quarter declined 36%.
Cardinal Health reported a strong third quarter of fiscal 2026, combining solid growth with a notable non-cash charge. Revenue rose 11% to $60.9 billion versus the prior-year quarter. Non-GAAP operating earnings increased 18% to $956 million and non-GAAP diluted EPS grew 35% to $3.17, helped by stronger segment performance, a lower non-GAAP tax rate and a lower share count.
GAAP results were weaker as operating earnings fell 30% to $509 million and diluted EPS declined 20% to $1.69, driven mainly by a $184 million goodwill impairment in the Navista & ION reporting unit. The Pharmaceutical and Specialty Solutions segment posted 11% revenue growth and 18% profit growth, while the Other segment grew revenue 31% and profit 34%. Cardinal Health raised its fiscal 2026 non-GAAP EPS outlook to $10.70–$10.80, implying 30%–31% growth, and lifted adjusted free cash flow guidance to $3.3–$3.7 billion. The company also reduced debt, brought its leverage ratio to 3.0x and completed $1.0 billion of share repurchases year-to-date.
Vanguard Capital Management reported beneficial ownership of 17,635,857 shares of Cardinal Health common stock, representing 7.49% of the class as reported on this Schedule 13G. The filing shows sole dispositive power over 17,635,857 shares and sole voting power over 2,347,148 shares. The filing is signed on 04/29/2026.
Cardinal Health Inc Schedule 13G: Vanguard Portfolio Management reports beneficial ownership of 13,786,683 shares of Common Stock, representing 5.85% of the class as reported. The filing shows sole voting power for 54,374 shares and sole dispositive power for 13,786,683 shares. The disclosure states these holdings reflect securities managed or advised by Vanguard Portfolio Management LLC and specified affiliates and fund sleeves.
Hall Patricia Hemingway reported acquisition or exercise transactions in this Form 4 filing.
Cardinal Health director Patricia Hemingway Hall reported an equity award rather than an open-market trade. She received 381 Common Shares in the form of additional RSUs in connection with her elevation to Chair of the Board, effective March 20, 2026, at a reference price of $207.83 per share. Following this grant, she directly holds 28,645 Common Shares.
The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A regarding Cardinal Health Inc. Common Stock. The filing states that, following an internal realignment effective January 12, 2026, The Vanguard Group reports 0 shares beneficially owned and 0% of the class. The amendment explains certain subsidiaries and business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and that The Vanguard Group no longer is deemed to have beneficial ownership over securities held by those subsidiaries. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Cardinal Health, Inc. reported that on March 2, 2026, Senior Vice President and Chief Accounting Officer Mary Scherer notified the company of her intention to retire in February 2027. The company plans to conduct a search for her successor.
Scherer will continue serving as Chief Accounting Officer until a new executive is identified and onboarded to support a smooth transition in the company’s accounting leadership.
Cardinal Health Chief Information Officer Michelle D. Greene reported two open-market sales of Cardinal Health common shares. On February 27, 2026, she sold 100 shares at $228.55 and 2,646 shares at $228.47, for a total of 2,746 shares sold. After these transactions, she directly owned 12,230 common shares of Cardinal Health.
Cardinal Health, Inc. submitted a Form 144 notice indicating a proposed sale of 2,746 common shares with a filing date of 02/27/2026. The disclosure lists restricted stock vesting events of 1,973 shares on 08/15/2024 and 773 shares on 03/15/2024.